This Month in JNM

March 2, 2020

Discussions with Leaders—JNM's series of interviews with leaders in nuclear and molecular imaging and therapy continues with a conversation with David Collingridge, editor-in-chief of The Lancet Oncology and publishing director of The Lancet specialty journals. Page 307

The State of the Art—The future of theranostics: Solnes and colleagues provide an overview of already approved theranostic agents and those in development and discuss the potential impacts on cancer and on the field of nuclear medicine. Page 311

18F-FDG or bacteria-targeting tracers? Chen and Dilsizian offer an educational overview of 18F-FDG PET/CT in cardiovascular device infection diagnosis, the strengths and limitations of bacteria-targeting radiotracers for infection imaging, and the pros and cons of 18F-FDG versus bacteria-targeting tracers. Page 319

PET/CT and tumor progression in OPSCC: Wu and colleagues describe development of quantitative imaging features on 18F-FDG PET and contrast CT imaging for use as markers to assess early response and predict outcomes in oropharyngeal squamous cell carcinoma. Page 327

18F-Choline PET/MRI for prostate biopsy: Davenport and colleagues detail the results of a prospective single-arm clinical trial to determine whether 18F-choline PET/multiparametric MRI can improve the specificity of multiparametric MRI of the prostate in patients with Gleason ≥3+4 prostate cancer. Page 337

Interobserver agreement in 18F-NaF PET/CT: Zacho and colleagues evaluate interobserver agreement on patient and lesion levels for 18F-sodium fluoride PET/CT detection of bone metastases in patients with prostate cancer. Page 344

First-line 90Y for uveal melanoma: Ponti and colleagues explore the safety and efficacy of 90Y selective internal radiation therapy as first-line therapy in patients with uveal melanoma metastatic to the liver. Page 350

18F-Fluoroglutamine dynamic PET: Grkovski and colleagues investigate the pharmacokinetic properties of this radiotracer for imaging tumor glutamine flux and metabolism properties in patients with cancer. Page 357

18F-DOPA PET/CT and neuroblastoma: Piccardo and colleagues evaluate the diagnostic role of 18F-DOPA PET/CT at the time of staging in children with neuroblastoma, its ability to assess treatment response, and its prognostic value. Page 367

Special Contribution—AUC for differentiated thyroid: Donohoe and members of a cross-disciplinary work group present new appropriate use criteria for nuclear medicine in the evaluation and treatment of differentiated thyroid cancer. Page 375

Patient release after 131I therapy: Wu and colleagues report on results from a nationwide survey to evaluate whether practices regarding hospital release of differentiated thyroid cancer patients treated with 131I have changed since publication of NRC Regulatory Issue Summary 2011-01. Page 397

Total-body PSMA PET for bone staging: Pomykala and colleagues determine the relationship between serum prostate-specific antigen levels and the incidence of bone metastases detected by total-body 68Ga–prostate-specific membrane antigen-11 PET/CT and assess the effect of expanding the imaging field. Page 405

End-of-treatment PET in TB: Lawal and colleagues explore the impact of findings on end-of-treatment 18F-FDG PET/CT on tuberculosis relapse in patients treated with a standard regimen of antituberculous treatment for drug-sensitive pulmonary tuberculosis. Page 412

Featured Clinical Investigation Article—PET and inferior colliculi: Speck and colleagues use 18F-FDG PET to evaluate the glucose metabolism of the inferior colliculus and primary auditory cortex in patients with asymmetric hearing loss. Page 418

18F-ASEM PET in MCI: Coughlin and colleagues use this tracer to examine the relationship between the α7-nicotinic acetylcholine receptor and Alzheimer disease in elderly controls and in patients with mild cognitive impairment. Page 423

64Cu-ATSM as a redox imaging marker: Floberg and colleagues demonstrate that this 64Cu-labeled PET tracer, developed for hypoxia imaging, is dependent on cellular redox state, with or without hypoxia. Page 427

89Zr-HDL tracer guides CSF1R therapy: Mason and colleagues propose an 89Zr-labeled high-density lipoprotein nanotracer as a means of rapidly monitoring response to immunotherapy targeting tumor-associated macrophages. Page 433    Open Access

CDK4/6 inhibitor for PET: Ramos and colleagues detail development of an 18F-labeled cyclin-dependent kinase 4/6 inhibitor for breast cancer imaging. Page 437

Tumor-residualizing GRPR-targeted agents: Zhang and colleagues present a strategy using irreversible inhibitors of cysteine cathepsins as trapping agents to increase tumor retention of agonistic and antagonistic pharmacophores targeting the gastrin-releasing peptide receptor. Page 443

Thirty-day total-body PET: Rosenkrans and Cai provide perspective on the recent completion of development of total-body PET scanners and discuss a related article in this issue of JNM. Page 451

Featured Article of the Month—30-day 89Zr-antibody PET: Berg and colleagues investigate the technical feasibility and utility of the mini-EXPLORER PET for total-body imaging of 89Zr-labeled antibodies in rhesus monkeys up to 30 days after injection. Page 453

Preclinical PET/CT standardized protocols: McDougald and colleagues assess the variability of current preclinical PET/CT acquisition/reconstruction protocols across multiple centers and propose protocols for standardization of multicenter data for routine scanning in preclinical PET/CT laboratories. Page 461    Open Access

Multivendor, multicenter radiomic study: Pfaehler and colleagues detail the impact of harmonized image reconstruction on feature consistency, using 3D printed phantom inserts reflecting realistic tumor shapes and heterogeneity uptake. Page 469